Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

High-dose vitamin D does not reduce falls, fractures in healthy adults

Roshini Claire Anthony
19 May 2017

High-dose, monthly vitamin D3 supplementation does not reduce the risk of falls or fractures in healthy, older adults, according to a secondary and post-hoc analysis of the ViDA* trial.

“These findings – taken in conjunction with results from other trials – suggest that use of large monthly bolus doses of vitamin D does not confer overall benefit,” said the researchers led by Professor Kay-Tee Khaw from the University of Cambridge School of Clinical Medicine, Cambridge, UK. They called for further study to determine the effects of daily vitamin D doses, with or without concurrent calcium supplementation. [Lancet Diabetes Endocrinol 2017;doi:10.1016/S2213-8587(17)30103-1]

In this double-blind study conducted in New Zealand, individuals aged 50–84 years (mean age 65.9 years, 58 percent male, mean blood concentration of 25(OH)D at baseline, 63 nmol/L) were randomized to receive colecalciferol (vitamin D3, initial oral dose of 200,000 IU [5 mg] followed by 100,000 IU [2.5 mg] monthly, n=2,558) or placebo (n=2,552).

After a mean treatment duration of 3.4 years, incidence of one or more falls was comparable between individuals on vitamin D and placebo (52 percent [n=1,312] vs 53 percent [n=1,326], adjusted hazard ratio [adjHR], 0.99, 95 percent confidence interval [CI], 0.92–1.07; p=0.82).

The incidence of nonvertebral fractures was also similar between individuals on vitamin D and placebo (6 percent [n=156] vs 5 percent [n=136], adjHR, 1.19, 95 percent CI, 0.94–1.50; p=0.15).

In an accompanying commentary, Professor Roger Bouillon from the Clinical and Experimental Endocrinology unit at KU Leuven, Leuven, Belgium, advised caution when interpreting these findings, as the primary outcome of the trial was to identify cardiovascular effects of high-dose vitamin D supplementation, and that the study may not have been adequately powered to determine fracture prevention risk. [Lancet Diabetes Endocrinol 2017;doi:10.1016/S2213-8587(17)30140-7]

While the study was powered to assess the impact of vitamin D supplementation on falls, individuals with severe vitamin D deficiency tend to derive the most benefit from supplementation and very few participants in this study met this criteria, said Bouillon. Other studies have found an increased risk of falls and fractures following high annual doses of colecalciferol, he said. [JAMA 2010;303:1815-1822]

“Khaw and colleagues are prudent to make clear that their results show that higher than recommended doses given monthly do not benefit adults with a baseline vitamin D status that is regarded as fairly normal,” said Bouillon.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.